You’re using a public version of DrugPatentWatch with 5 free searches available | Register to unlock more free searches. CREATE FREE ACCOUNT

Last Updated: April 16, 2024

~ Buy the BELSOMRA (suvorexant) Drug Profile, 2024 PDF Report in the Report Store ~

CLINICAL TRIALS PROFILE FOR BELSOMRA

✉ Email this page to a colleague

« Back to Dashboard

All Clinical Trials for BELSOMRA

Subscribe to access the full database, or Try a Trial
Trial ID	Title	Status	Sponsor	Phase	Start Date	Summary
NCT02491788 ↗	Examination of the Effectiveness of Suvorexant in Improving Daytime Sleep in Shift Workers	Completed	Merck Sharp & Dohme Corp.	Phase 4	2016-02-01	The purpose of this study is to test the hypothesis that ingestion of the wake-inhibiting drug suvorexant 30 minutes prior to daytime sleep initiation in individuals working overnight shifts will significantly improve both objective (total sleep time, sleep efficiency, wake after sleep onset) and subjective (sleep quality) measures of daytime sleep.
NCT02491788 ↗	Examination of the Effectiveness of Suvorexant in Improving Daytime Sleep in Shift Workers	Completed	Stanford University	Phase 4	2016-02-01	The purpose of this study is to test the hypothesis that ingestion of the wake-inhibiting drug suvorexant 30 minutes prior to daytime sleep initiation in individuals working overnight shifts will significantly improve both objective (total sleep time, sleep efficiency, wake after sleep onset) and subjective (sleep quality) measures of daytime sleep.
NCT02491788 ↗	Examination of the Effectiveness of Suvorexant in Improving Daytime Sleep in Shift Workers	Completed	VA Palo Alto Health Care System	Phase 4	2016-02-01	The purpose of this study is to test the hypothesis that ingestion of the wake-inhibiting drug suvorexant 30 minutes prior to daytime sleep initiation in individuals working overnight shifts will significantly improve both objective (total sleep time, sleep efficiency, wake after sleep onset) and subjective (sleep quality) measures of daytime sleep.
NCT02527564 ↗	Efficacy of Suvorexant to Treat Insomnia Related to Bipolar Disorder	Recruiting	Merck Sharp & Dohme Corp.	Phase 4	2015-09-01	The purpose of this study is to evaluate the efficacy of suvorexant, added to existing medications, for treatment-resistant insomnia in individuals with bipolar disorder. The investigators hypothesize that participants receiving suvorexant for one week will experience significantly greater improvement in sleep duration compared to participants receiving placebo.
>Trial ID	>Title	>Status	>Sponsor	>Phase	>Start Date	>Summary

Clinical Trial Conditions for BELSOMRA

Condition Name

Chart
Table

Condition Name for BELSOMRA
Intervention	Trials
Insomnia	16
Sleep Initiation and Maintenance Disorders	2
Postoperative Delirium	2
Bipolar Disorder	2
[disabled in preview]	0
This preview shows a limited data set Subscribe for full access, or try a Trial

Condition MeSH

Chart
Table

Condition MeSH for BELSOMRA
Intervention	Trials
Sleep Initiation and Maintenance Disorders	20
Sleep Wake Disorders	7
Parasomnias	6
Disease	5
[disabled in preview]	0
This preview shows a limited data set Subscribe for full access, or try a Trial

Clinical Trial Locations for BELSOMRA

Trials by Country

Map
Table

Trials by Country for BELSOMRA
Location	Trials
United States	30
Canada	1
Japan	1
Australia	1
This preview shows a limited data set Subscribe for full access, or try a Trial

Trials by US State

Map
Table

Trials by US State for BELSOMRA
Location	Trials
California	5
Massachusetts	4
Michigan	4
Maryland	3
Washington	2
This preview shows a limited data set Subscribe for full access, or try a Trial

Clinical Trial Progress for BELSOMRA

Clinical Trial Phase

Chart
Table

Clinical Trial Phase for BELSOMRA
Clinical Trial Phase	Trials
Phase 4	20
Phase 2/Phase 3	1
Phase 2	8
[disabled in preview]	1
This preview shows a limited data set Subscribe for full access, or try a Trial

Clinical Trial Status

Chart
Table

Clinical Trial Status for BELSOMRA
Clinical Trial Phase	Trials
Recruiting	13
Completed	8
Not yet recruiting	6
[disabled in preview]	2
This preview shows a limited data set Subscribe for full access, or try a Trial

Clinical Trial Sponsors for BELSOMRA

Sponsor Name

Chart
Table

Sponsor Name for BELSOMRA
Sponsor	Trials
Merck Sharp & Dohme Corp.	8
Henry Ford Health System	3
Stanford University	3
[disabled in preview]	3
This preview shows a limited data set Subscribe for full access, or try a Trial

Sponsor Type

Chart
Table

Sponsor Type for BELSOMRA
Sponsor	Trials
Other	41
Industry	12
NIH	5
[disabled in preview]	4
This preview shows a limited data set Subscribe for full access, or try a Trial

Make Better Decisions: Try a trial or see plans & pricing

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.